Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis

Overview of attention for article published in Arthritis Research & Therapy, March 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

So far, Altmetric has seen 1 review on a research highlight platform.

This research output was recommended by a member of Faculty Opinions.

This page shows the most recent research highlights that mention this research output.

Click here to find out how to access more activity.